Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease
- 1 December 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 110 (12), 4132-4133
- https://doi.org/10.1182/blood-2007-08-106187
Abstract
To the editor: Rituximab is active as initial treatment for HIV-associated multicentric Castleman disease (HMCD). Its efficacy and safety in rituximab pretreated, relapsed patients has not been previously described. We retreated a series of patients with rituximab at histologically confirmedKeywords
This publication has 13 references indexed in Scilit:
- Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman diseaseAnnals of Hematology, 2005
- Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman diseaseAmerican Journal of Hematology, 2005
- Maximizing Therapeutic Benefit of Rituximab: Maintenance Therapy Versus Re-Treatment at Progression in Patients With Indolent Non-Hodgkin's Lymphoma—A Randomized Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Clinical Oncology, 2005
- Fifty years of multicentric Castleman's diseaseActa Oncologica, 2004
- Resolution of AIDS-related Castleman's Disease with Anti-CD20 Monoclonal Antibodies is Associated with Declining IL-6 and TNF-α LevelsLeukemia & Lymphoma, 2004
- Multicentric Castleman's diseaseAIDS, 2004
- Rituximab therapy for HIV-associated Castleman diseaseBlood, 2003
- Prolonged remission of HIV-associated multicentric Castelmanʼs disease with an anti-CD20 monoclonal antibody as primary therapyAIDS, 2003
- Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine–rituximabThe Hematology Journal, 2003
- Long-term remission of Kaposi sarcoma–associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapyBlood, 2001